Risk factors associated with survival outcomes for lymphoma patients after anti-CD19 CAR T-cell infusion
| Risk factor . | Prognostic role . |
|---|---|
| • Higher CAR T-cell product expansion | ORR: OR 1.268 (95% CI: 1.062-1.676; p < 0.05)26 |
| • +1 month 18FDG-PET/CT disease evaluation | • Prognostic role on relapse and PFS (Deauville score)29 • SUV max useful in predicting progression for patients in PR/SD30 • Deauville score combined with SUV variation allowed better stratification of patients at day +30 DS4-531 |
| • Tumor burden measured by liquid biopsy (VDJ ctDNA) | • Prognostic role after infusion at +1 week, +1 month, and +3 months; also, useful in stratifying patients with radiological SD/PR at +1 month32 |
| Risk factor . | Prognostic role . |
|---|---|
| • Higher CAR T-cell product expansion | ORR: OR 1.268 (95% CI: 1.062-1.676; p < 0.05)26 |
| • +1 month 18FDG-PET/CT disease evaluation | • Prognostic role on relapse and PFS (Deauville score)29 • SUV max useful in predicting progression for patients in PR/SD30 • Deauville score combined with SUV variation allowed better stratification of patients at day +30 DS4-531 |
| • Tumor burden measured by liquid biopsy (VDJ ctDNA) | • Prognostic role after infusion at +1 week, +1 month, and +3 months; also, useful in stratifying patients with radiological SD/PR at +1 month32 |
ctDNA, circulating tumor DNA; OR, odds ratio; ORR, overall response rate; PFS, progression-free survival; PR, partial response; SD, stable disease; VDJ, variable, diversity, and joining gene segments.